Close Menu

NEW YORK (GenomeWeb) — Precipio said today that the University of Cincinnati Medical Center (UCMC) will use its ICE-COLD PCR (ICP) mutation enrichment technology in a study screening for clinically actionable mutations in non-small cell lung cancer (NSCLC) patients.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.